Lassaletta A; Zapotocky M; Mistry M; Ramaswamy V; Honnorat M; Krishnatry R; Stucklin AG; Zhukova N; Arnoldo A; Ryall S; Ling C; McKeown, T; Loukides J; Cruz O; de Torres C; Ho CY; Packer RJ; Tatevossian R; Qaddoumi I; Harreld JH; Dalton JD; Mulcahy-Levy J; Foreman N; Karajannis MA; Wang SY; Snuderl M; Rao AN; Giannini C; Kieran M; Ligon KL; Garre ML; Nozza P; Mascelli S; Raso A; Mueller S; Nicolaides T; Silva K; Perbet R; Vasiljevic A; Conter CF; Frappaz D; Leary S; Crane C; Chan A; Ng HK; Shi ZF; Mao Y; Finch E; Eisenstat D; Wilson B; Carret AS; Hauser, Péter; Sumerauer D; Krskova L; Larouche V; Fleming A; Zelcer S; Jabado N; Rutka JT; Dirks P; Taylor MD; Chen SY; Bartels U; Huang A; Ellison DW; Bouffet E; Hawkins C; Tabori U
(2017)
Purpose BRAF V600E is a potentially highly targetable mutation detected in a subset of pediatric low-grade gliomas (PLGGs). Its biologic and clinical effect within this diverse group of tumors remains unknown. Patients and ...